Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Go ahead and fool yourself! ANAVEX just completed a Phase3 AD TRIAL of 509 early ALZHEIMER’S patients! Let’s wait for the TLD. You will see then.
The TLD for ANAVEXs A 2-73 PHASE III trial will shut SAVA permanently! TLD will be done in FALL 2022! Wait a minute, it is already FALL 2022!
SAVA is based on the A-Beta thesis, which has failed clinical trials many times over the last 50 years!
The A 2-73 is a new MOA based on Sigma1 Agonism activation. It has proven efficacy in RETTS and PDD.
SAVA doesn’t hold a stick to A 2-73!
Once the PHASE III DATA shows overwhelming efficacy for A 2-73 in ALZHEIMER’S, there is no denial of that!
Data speaks in absolute terms.
BP will have to live with what trials produce.
FDA will have to live with what the trials produce. The FDA will not ask for additional data when the data is conclusively showing efficacy!!
Don’t be idiotic about this stuff!
The BS will disappear to where only the data counts. Specially after the ADUHELM FIASCO. If the data shows the efficacy then bingo for ANAVEX!
The biggest influence on the FDA will be the efficacy shown by the science indicated by the trial data. Period.
There will be NO Denial of the trial data!!
Partnership has no bearing on efficacy and cannot have any influence on the pristine characters at the FDA!
It’s nice to see that the media sources refer to ANAVEXs AD trial as “PHASE III”!
You should just be content with the A-Beta thesis papier-mâché honeypot stocks ( SAVA BIIB ALEC … ). By the time you finally realize how the ANAVEX MOU SIGMA1 thesis does work the AVXL stock will be $2498.00 a share!
Not! Very not!
Perhaps we are seeing buyout paranoia on the part of Missling? He wants to get data from all 3 sets of trials to be simultaneously evaluated by the FDA so the MC of AVXL appreciates instantaneously for AD, PD, PDD, RETTS. That would insure we get buyout offers at a maximal price!
Nothing!
Revenues after within 1 year after approval of ANAVEX A 2-73 for ALZHEIMER’S will be between “$13B and $68B”, to quote Dr Missling. That puts the stock price any where between $1000.00 and $10000.00.
$1249.00 is low after TLD! Ok $2498.00 then!
Mike the POS-guy is calling for 7s, every one else is thinking ANAVEX can’t be anything but $1249.00 after TLD.
Another p3 trial will not be required. ANAVEX just completed a p3 trial of 509 patients. Have you noticed all ANAVEX trials have completed with extremely good results!!! Stellar actually!
ANAVEX P3 AD TRIAL completed before June 30, 2022, about 3 months ago! ANAVEX discussed that trial with the FDA
before that ! The DSMB reviewed and blessed ANAVEXs trial procedures. It would be totally fruitless for ANAVEX to talk to you!
ANAVEX has already talked to the FDA about it’s trials. Do they have to talk to you?
It’s Fall already!
Some things don’t need explanation. Just let the new data from p3 do the talking.
By your expertise, that’s a swag! At best.
Too many people are just making up stuff! The FDA will under proper circumstances actually approve ANAVEX A 2-73! That has nothing to do with recession or interest rate changes!
Cheaper.
Zymund Saks comes to mind.
Blind statements!! Completely! Sigma1 has already proven its worth. No erosion will occur!
Silicon Valley produced well over 100 125 baggers since year 1995!
Not 15 months. I have been in it to win it for over 96 months. Since 2015.
$1249 AVXL price is not very far off. However, I expect it at Christmas 2023 or NEW YEARS DAY 2024.
AVXL isn’t a spec stock. There isn’t any speculation going on, just certain long investing! All the honeypots ( BIIB SAVA ANVS … )are speculation.
Get ready, Fall is here. Sept 21 is next week. P3 AD completed 3 months ago! TLD any day. Approval not far away. ALZHEIMER’S PATIENTS GETTING BETTER! $20B revenues will appear! AVXL will be much, much, much higher!
Boi you got that. Let’s just see what gets announced as TLD for P3 AD trials for ANAVEX A 2-73. Labor Day is past; FALL is coming up FAST! TLD will be jaw dropping!
Did SAVA get to $1249? I didn’t see that?
SAVA is a suckers bet; just A-Beta BS!
There is no value in timing stock market events; it cannot be done! Any stock purchase strategy that depends on timing is death. Buffett relies on buy and hold over long term; only thing viable!
Labor Day is past. Fall is coming fast.
That’s total BULLSHIT! Longs are strong!
Fall is getting closer, and AVXL at $1249 getting closer.
Not so sure retail will ever be out of AVXL! A number of shareholder votes have established several measures to make a hostile buyout impossible! The bug three will end up owning a lot of shares, but not controlling the company because Missling has some control of the management. Additionally, Nevada has good laws that aid the prevention of hostile takeovers! Can anyone provide reinforcement of this?
Only you are confused. Rules are crystal clear!
Looks like the WALL STREET biggies are still living in total ignorance. They still seem to believe that no revenue equals no value. And still expect AD will be solved only by A-Beta removal! Idiocy!
They will be surprised that A 2-73 really remediates AD. And the AVXL is above $2597!
SAVA is a no account stock based on 50 yo technology of A-Beta removal!